Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2023-05-04 Earnings Release
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2023, by Cardiff Oncology, Inc. It announces the issuance of a press release containing financial results for the first quarter ended March 31, 2023. The text explicitly states that the information is being furnished and is not considered "filed" for certain regulatory purposes, and it includes a press release as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length is 3262 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights only, not the full quarterly report (IR) or annual report (10-K).
2023-05-04 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-04 English
ARS
Annual Report
2023-04-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filing for Cardiff Oncology, Inc., containing information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on, voting instructions, and availability of proxy materials. It explicitly states it is a 'Definitive Additional Materials' filing related to the proxy statement. The content focuses on soliciting shareholder votes and providing proxy materials, not the actual annual report or financial statements. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is about 5,071 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is PSI with high confidence.
2023-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-27 English
FORM 4
Director's Dealing
2023-03-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.